Elecoglipron delivered dose-dependent weight loss ranging from 2.6% with 5mg to 10.5% with 75mg weekly titration over 26 weeks in 310 adults with obesity or overweight. This represents the first successful oral small-molecule GLP-1 receptor agonist to reach phase 2 trials, potentially addressing a major limitation of current injectable GLP-1 drugs like semaglutide and tirzepatide. The oral formulation eliminates injection barriers that prevent many patients from accessing these transformative obesity treatments. The 10.5% weight loss with the highest dose approaches the efficacy of injectable GLP-1 medications, though direct comparisons require caution given different study populations and durations. However, the 25% discontinuation rate suggests tolerability challenges remain. The convenience of once-daily oral dosing without food restrictions could dramatically expand treatment accessibility for the 650 million adults with obesity worldwide. This finding represents a significant pharmaceutical breakthrough that could democratize GLP-1 therapy, though longer-term safety data and real-world adherence patterns will determine its ultimate clinical impact compared to established injectable alternatives.